The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.
Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
1 | 1 | 1 | 19 |
Growth
|
79 | 100 | 91 | 29 |
Safety
|
35 | 35 | 99 | 99 |
Sentiment
|
37 | 84 | 61 | 62 |
|
27 | 27 | 16 | 26 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Analyst Opinions
|
78 | 75 | 44 | 13 |
Opinions Change
|
31 | 72 | 25 | 50 |
Pro Holdings
|
n/a | 82 | 73 | 98 |
Market Pulse
|
44 | 35 | 62 | 52 |
Sentiment
|
37 | 84 | 61 | 62 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
1 | 1 | 1 | 19 |
Growth
|
79 | 100 | 91 | 29 |
|
35 | 35 | 99 | 99 |
Combined
|
15 | 15 | 74 | 74 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Price vs. Sales (P/S)
|
23 | 27 | 19 | 52 |
Price vs. Earnings (P/E)
|
15 | 7 | 18 | 22 |
Price vs. Book (P/B)
|
4 | 9 | 9 | 30 |
Dividend Yield
|
1 | 1 | 1 | 1 |
Value
|
1 | 1 | 1 | 19 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Revenue Growth
|
82 | 81 | 75 | 39 |
Profit Growth
|
58 | 74 | 37 | 39 |
Capital Growth
|
15 | 100 | 89 | 61 |
Stock Returns
|
95 | 100 | 85 | 41 |
Growth
|
79 | 100 | 91 | 29 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Leverage
|
100 | 100 | 100 | 100 |
Refinancing
|
19 | 20 | 33 | 41 |
Liquidity
|
1 | 1 | 86 | 86 |
|
35 | 35 | 99 | 99 |
Discover high‑ranked alternatives to Corcept Therapeutics and broaden your portfolio horizons.
The Obermatt Advantage
Choose the Obermatt subscription that best fits your needs.